key: cord-0735772-579yer7i
authors: Wright, Daniel F. B.; Kirkpatrick, Carl M. J.
title: Science fiction has become reality: Best practice for future viral pandemics
date: 2021-08-02
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14997
sha: 4b9c31b2ee17c2731a195f8973fabd0be897ae91
doc_id: 735772
cord_uid: 579yer7i

nan

Severe Acute Respiratory Syndrome (SARS), while concerning, appeared to be contained or remained regional. To the lay public, a truly global pandemic might have seemed like something that belonged in the realm of science fiction.

Science fiction writers often explore dystopian themes and use their work as a vehicle for thought experiments about how society might cope with major global events. Perhaps unsurprisingly, uncontrolled viral pandemics are a recurring theme. The idea that a global response will be needed, uniting nations, private industry, and health organisations against a common (viral) foe, is both a familiar feature of our current human existence and is evident in several works of science fiction. Novels such as Dean Kootnz's 1981 work The Eyes of Darkness are claimed to have predicted the SARs-COV-2 outbreak, although this does not appear hold in the detail. 1 Other works (e.g., Vylar Kaftan's 2012 short story Lion Dance) feature now all too familiar pandemic practices such as the closure of schools, social distancing, the requirement for masks in public places, and self-isolation. 2 Even the 1960's television show Star Trek toyed with the theme of a global pandemic in an episode called "Miri" (aired October 1966). In this program, the entire population of a planet was a risk of extinction due to an invisible pathogen which required the rapid development and testing of a vaccine.

In the real world, science fiction became reality in late 2019 with the beginning of the current SARs-COV-2 outbreak in Wuhan, China.

The declaration by the World Health Organisation in March 2020 3 that the outbreak was a "pandemic" signalled that a coordinated global response was going to be needed to contain the disease. What followed was an unprecedented escalation of scientific efforts to rapidly develop vaccines against the SARs-COV-2 virus, identify potential drug treatments with expeditated clinical trials, and repurpose existing drugs to treat COVID-19 disease.

Reflecting on the first 6 months of the pandemic, there was confidence, and perhaps too much comfort, that our available vaccines and approved medicines, developed through suitably rigorous and adaptable drug development and regulatory pathways, would be sufficient to navigate the world out of the SARs-COV-2 pandemic.

What became apparent was that drug development and regulatory communities were caught "flat-footed" by COVID-19, mired in traditional slow-moving development programmes and regulatory pathways with little room to pivot quickly in response to a global emergency. This was despite calls for adaptive licensing and other regulatory pathways for niche diseases to accelerate development to particularly vulnerable populations in the preceding decade. 4 In this themed issue, we approached groups and researchers who An important concern is that the lessons learned during the past 18 months will be quickly forgotten once the SARs-COV-2 pandemic has ended. This was arguably the case in the early 2000s when SARS-COV-1 disappeared and resources to combat the outbreak were redirected elsewhere. Preparedness for future pandemics therefore requires the development of policies and processes to identify, react to, and control future pandemics in a timely and efficient manner. This is introduced by Dodds et al. 5 

Davda et al. 6 who present a five-stage blueprint that will allow us to be prepared for, and react to, future viral outbreaks. Importantly, the blueprint is centred on pre-pandemic preparedness, including surveillance for new pathogens, high through-put screening for potential therapeutic options using human derived pulmonary cells, and the identification of key pharmacological indices such as IC50 values (or better EC90 values) using prior work on reference viruses. 6 In terms of co-operation, the need for data sharing and transparency in clinical trials globally to combat mis-information, poorly conceived studies, and fraudulent therapeutic claims that occurred during the first 6-12 months of the pandemic is essential. Importantly, systems must now be put in place, as a defined act of preparedness, to ensure this is a reality before the next pandemic. 7 This includes careful review of the role of traditional medicines in the supportive care of COVID-19 disease 13 In the current pandemic, the elderly, particularly those in residential aged care, were the population particularly vulnerable to COVID-19, 14 while paediatrics were thought to be of low risk of infection and transmissibility. This further highlights the need for co-operation to improve the translation of available data to under-represented populations such as paediatrics and pregnant patients. 15 These populations will need prophylaxis or treatment or indeed may be the next vulnerable target population due to an antigenic viral shift.

The current COVID-19 era will effectively end when the SARs-COV-2 virus is contained, the global population is vaccinated, and life returns to some semblance of the pre-COVID world. The lessons learned during the COVID-19 pandemic, as highlighted in the papers presented here, can play an important role in how we prepare, implement, and coordinate effective responses for future pandemics. When future generations look back at this time in history, they should see more than fodder for new science fiction stories. Instead, we hope that this era will be recognised as the beginning of global scientific programmes and practices to prepare the world for future pandemics and enabled the necessary reset of how we develop and approve medicines and vaccines. The COVID-19 events were the catalyst needed to align in vitro, in silico, in vivo, and regulatory science in highly coordinated ways to answer urgent questions. These approaches must now be considered the new "best practice" for all medicines and vaccine development moving forward.

There are no competing interests to declare. 

Guardian book review

Pandemics, epidemics, viruses, plagues, and disease: comparative frequency analysis of a cultural pathology reflected in science fiction magazines from 1926 to 2015

World Health Organization. Speeches. WHO Director-General's opening remarks at the media briefing on COVID-19. 11 Mar

Adaptive licensing: taking the next step in the evolution of drug approval

Model-informed drug repurposing: a pharmacometric approach to novel pathogen preparedness, response and retrospection

Blueprint for pandemic response: focus on translational medicine, clinical pharmacology and pharmacometrics

Racing to immunity: journey to a COVID-19 vaccine and lessons for the future

The impact of the global COVID-19 pandemic on the conduct of clinical trials: return to normalcy by considering the practical impact of a structured ethical analysis

Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: an example in SARS-CoV-2

Model-informed drug repurposing: viral kinetic modelling to prioritize rational drug combinations for COVID-19

Dosing will be a key success factor in repurposing antivirals for COVID-19

A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments

Traditional medicines for COVID-19: perspectives from clinical pharmacologists

Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond

Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women